Charles Schwab’s Intersect ENT, Inc XENT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-242,370
| Closed | -$6.79M | – | 3723 |
|
|
2022
Q1 | $6.79M | Buy |
242,370
+3,942
| +2% | +$108K | ﹤0.01% | 2134 |
|
|
2021
Q4 | $6.51M | Buy |
238,428
+10,099
| +4% | +$274K | ﹤0.01% | 2221 |
|
|
2021
Q3 | $6.21M | Buy |
228,329
+232
| +0.1% | +$5.74K | ﹤0.01% | 2270 |
|
|
2021
Q2 | $3.9M | Buy |
228,097
+7,912
| +4% | +$148K | ﹤0.01% | 2470 |
|
|
2021
Q1 | $4.6M | Buy |
220,185
+4,778
| +2% | +$110K | ﹤0.01% | 2342 |
|
|
2020
Q4 | $4.93M | Buy |
215,407
+2,875
| +1% | +$54.7K | ﹤0.01% | 2227 |
|
|
2020
Q3 | $3.47M | Sell |
212,532
-2,084
| -1% | -$37.7K | ﹤0.01% | 2252 |
|
|
2020
Q2 | $2.91M | Buy |
214,616
+20,411
| +11% | +$237K | ﹤0.01% | 2285 |
|
|
2020
Q1 | $2.3M | Buy |
194,205
+3,709
| +2% | +$82.2K | ﹤0.01% | 2222 |
|
|
2019
Q4 | $4.74M | Buy |
190,496
+3,817
| +2% | +$77.4K | ﹤0.01% | 2044 |
|
|
2019
Q3 | $3.18M | Buy |
186,679
+5,119
| +3% | +$93.2K | ﹤0.01% | 2202 |
|
|
2019
Q2 | $4.13M | Buy |
181,560
+7,269
| +4% | +$196K | ﹤0.01% | 2065 |
|
|
2019
Q1 | $5.6M | Buy |
174,291
+6,395
| +4% | +$198K | ﹤0.01% | 1930 |
|
|
2018
Q4 | $4.73M | Sell |
167,896
-22,061
| -12% | -$646K | ﹤0.01% | 1934 |
|
|
2018
Q3 | $5.46M | Buy |
189,957
+11,004
| +6% | +$331K | ﹤0.01% | 2001 |
|
|
2018
Q2 | $6.7M | Buy |
178,953
+11,590
| +7% | +$455K | ﹤0.01% | 1848 |
|
|
2018
Q1 | $6.58M | Buy |
167,363
+6,480
| +4% | +$237K | 0.01% | 1788 |
|
|
2017
Q4 | $5.21M | Buy |
160,883
+45,444
| +39% | +$1.36M | ﹤0.01% | 1898 |
|
|
2017
Q3 | $3.6M | Buy |
115,439
+20,700
| +22% | +$613K | ﹤0.01% | 2056 |
|
|
2017
Q2 | $2.65M | Sell |
94,739
-26,099
| -22% | -$591K | ﹤0.01% | 2124 |
|
|
2017
Q1 | $2.07M | Buy |
120,838
+6,963
| +6% | +$97.5K | ﹤0.01% | 2188 |
|
|
2016
Q4 | $1.38M | Buy |
113,875
+6,546
| +6% | +$84.7K | ﹤0.01% | 2323 |
|
|
2016
Q3 | $1.7M | Buy |
107,329
+41,581
| +63% | +$626K | ﹤0.01% | 2219 |
|
|
2016
Q2 | $851K | Buy |
65,748
+14,340
| +28% | +$224K | ﹤0.01% | 2400 |
|
|
2016
Q1 | $977K | Buy |
51,408
+1,020
| +2% | +$18.5K | ﹤0.01% | 2358 |
|
|
2015
Q4 | $1.13M | Sell |
50,388
-1,524
| -3% | -$30.1K | ﹤0.01% | 2337 |
|
|
2015
Q3 | $1.22M | Buy |
51,912
+31,944
| +160% | +$881K | ﹤0.01% | 2317 |
|
|
2015
Q2 | $572K | Buy |
19,968
+11,568
| +138% | +$303K | ﹤0.01% | 2629 |
|
|
2015
Q1 | $217K | Buy |
+8,400
| New | +$192K | ﹤0.01% | 2931 |
|
Charles Schwab's XENT Position: Q2 2022 in Review
Charles Schwab sold out of Intersect ENT, Inc (XENT) in Q2 2022, closing a stake of 242,370 shares — an estimated $6.79M sold.
Charles Schwab first reported a position in XENT in Q1 2015 and held it in 29 quarters. The position peaked at $6.79M in Q1 2022. 0 funds tracked by Wall St. Rank hold XENT as of Q2 2022.
- Charles Schwab reported no remaining Intersect ENT, Inc position as of Q2 2022 after selling out during the quarter.
- Charles Schwab sold 242,370 Intersect ENT, Inc shares in Q2 2022, an estimated $6.79M.
- Charles Schwab first reported a position in Intersect ENT, Inc in Q1 2015 and held it in 29 quarters.
- Charles Schwab's Intersect ENT, Inc position peaked at $6.79M in Q1 2022.
- 0 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q2 2022.
Based on Charles Schwab's 13F filing for Q2 2022, filed 15 Aug 2022.